More on ImmunoCellular Q2 results


ImmunoCellular Therapeutics (IMUC -2.6%) Q2 results: Revenues: $0; Operating Loss: ($2.4M) (-11.2%); Net Loss: ($2.2M) (-999%); Loss Per Share: ($0.04); Quick Assets: $25.7M (-6.9%).

No guidance given.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs